Infant Bacterial Therapeutics AB (OSTO:IBT B) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Infant Bacterial Therapeutics AB's cash to debt ratio for the quarter that ended in Mar. 2025 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Infant Bacterial Therapeutics AB could pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's Cash-to-Debt or its related term are showing as below:

OSTO:IBT B' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 11 years, Infant Bacterial Therapeutics AB's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

OSTO:IBT B's Cash-to-Debt is ranked better than
99.93% of 1464 companies
in the Biotechnology industry
Industry Median: 7.685 vs OSTO:IBT B: No Debt

Infant Bacterial Therapeutics AB Cash-to-Debt Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Infant Bacterial Therapeutics AB Cash-to-Debt Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Infant Bacterial Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Infant Bacterial Therapeutics AB's Cash-to-Debt

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Infant Bacterial Therapeutics AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Infant Bacterial Therapeutics AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Infant Bacterial Therapeutics AB had no debt ⁽¹⁾.

Infant Bacterial Therapeutics AB's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

Infant Bacterial Therapeutics AB had no debt ⁽¹⁾.

Infant Bacterial Therapeutics AB (OSTO:IBT B) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Infant Bacterial Therapeutics AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines

Infant Bacterial Therapeutics AB (OSTO:IBT B) Cash-to-Debt : No Debt (1) (As of Mar. 2025)